Ajanta Pharma Ltd's Q4FY25 Quarterly Results

Result Summary

• Ajanta Pharma Ltd reported a 7.4% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Mar (Q4FY25). On a year-on-year (YoY) basis, it witnessed a growth of 18.6%.
• Its expenses for the quarter were down by 6.6% QoQ and up 5.9% YoY.
• The net profit decreased 13.0% QoQ and increased 65.8% YoY.
• The earnings per share (EPS) of Ajanta Pharma Ltd stood at 16.1 during Q4FY25.

Financial Statments for Q4FY25

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Ajanta Pharma Ltd is a prominent pharmaceutical company engaged in the development, manufacturing, and marketing of a wide range of pharmaceutical products. The company's portfolio includes branded generics, over-the-counter drugs, and active pharmaceutical ingredients (APIs). Established in 1973, Ajanta Pharma has a strong presence in both domestic and international markets. The company is known for its focus on therapeutic segments such as cardiology, ophthalmology, dermatology, and pain management. As of the data available up to October 2023, Ajanta Pharma has been consistently expanding its product offerings and exploring new markets to enhance its global footprint.

Revenue

In the fourth quarter of fiscal year 2025 (Q4FY25), Ajanta Pharma reported a total income of ₹1089.58 crores. This marks a year-over-year (YoY) increase of 18.6% compared to ₹918.67 crores in Q4FY24. However, compared to the previous quarter, Q3FY25, which recorded a total income of ₹1176.57 crores, there was a quarter-over-quarter (QoQ) decline of 7.4%. This fluctuation in revenue can be observed in the financial performance over the quarters, illustrating the dynamics in sales or market conditions that the company experienced within the fiscal year.

Profitability

Ajanta Pharma's profitability metrics for Q4FY25 reflect significant changes over the year. The company reported a profit before tax of ₹278.04 crores, representing an impressive YoY growth of 82.9% from ₹152.05 crores in Q4FY24. However, on a QoQ basis, there was a decline of 9.5% from ₹307.39 crores reported in Q3FY25. The profit after tax for Q4FY25 was ₹202.72 crores, showing a YoY increase of 65.8% from ₹122.25 crores in Q4FY24. Despite the YoY growth, there was a QoQ decline of 13.0% from the ₹232.88 crores recorded in the previous quarter. The Earnings Per Share (EPS) for Q4FY25 was ₹16.10, compared to ₹9.50 in Q4FY24, reflecting a YoY growth of 69.5%, though it declined by 13.4% QoQ from ₹18.60 in Q3FY25.

Operating Metrics

Ajanta Pharma's operating expenses in Q4FY25 totaled ₹811.54 crores, an increase of 5.9% compared to ₹766.62 crores in Q4FY24, indicating a controlled growth in expenses relative to income. On the other hand, compared to Q3FY25, where total expenses were ₹869.18 crores, there was a QoQ reduction of 6.6%. The tax expense for Q4FY25 stood at ₹75.32 crores, which is a significant YoY increase of 152.8% from ₹29.80 crores in Q4FY24 and a slight QoQ increase of 1.1% from ₹74.51 crores in Q3FY25. These metrics provide insights into the company's cost management practices and tax obligations during the quarter under review.